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Abstract
Antitumor effects of the combination chemotherapy with hemolytic streptococcus prepara-
tion, OK-432, and various anticancer agents were observed on experimental tumors and human
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gen mustard N-Oxide or Bleomycin was remarkably effective on rodent transplantable tumors
such as Ehrlich carcinoma, sarcoma-lOO and rat ascitic hepatoma AH-66. As for the mode of
action of OK-432, besides a direct action on cancer cells, a host-mediated action appears to be
also involved. Clinical trials were made on 14 cases with various advanced cancers, and favorable
response was obtained in 5 with lung cancer. Fever was the major side effect of OK-432 and there
was no evidence of bone marrow suppression.
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Abstract: Antitumor effects of the combination chemotherapy
with hemolytic streptococcus preparation, OK-432, and various anti-
cancer agents were observed on experimental tumors and human
cancers. Experimental studies revealed that combined use of OK-432
with Mitomycin C, Nitrogen mustard N-Oxide or Bleomycin was re-
markably effective on rodent transplantable tumors such as Ehrlich
carcinoma, sarcoma-lOO and rat ascitic hepatoma AH-66. As for the
mode of action of OK-432, besides a direct action on cancer cells, a
host-mediated action appears to be also involved. Clinical trials were
made on 14 cases with various advanced cancers, and favorable re-
sponse was obtained in 5 with lung cancer. Fever was the major side
effect of OK-432 and there was no evidence of bone marrow suppres-
sion.
Major efforts have been exerted to increase anti-tumor effect and to
minimize adverse effects in cancer chemotherapy. Multiple combined therapy
is one of the approaches which have been devised for this purpose and this
therapy has achieved a considerable progress in recent years.
OK-432, developed by OKAMOTO et ai. (1) as an anti-tumor agent derived
from hemolytic streptococcus, has been the subject of reports indicating its
effectiveness in topical as well as systemic administration, although there are
still unanswered questions concerning its mechanism of action (2, 3). Our
experience with this drug in a small number of clinical cases has not yet
established any definitive effectiveness, but it did not cause bone marrow
suppression, which is a major problem in cancer chemotherapy.
Combination with OK-432 and available anticancer agents may produce
desirable anticancer effect with minimal toxicity, since they were qualitatively
different in toxicity and also may be different in mechanism of action.
Initially, experimental studies involving combined use of OK-432 with
Mitomycin C (MMC) were carried out, and then this combination was extended
to clinical use.
MATERIALS AND METHODS
OK-432: OK-432 was prepared from a low virulent Strain Su of streptococcus
haemolyticus established by OKAMOTO et ai. One KE (Klinische Einheit, i. e.,
411
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unit) contains O. 1 mg of prepared hemolytic streptococci by dry weight.
Animals: Six-week-old male ICR mice were employed for Ehrlich Carci-
noma and Sarcoma-l80, and six-week-old male Donryu rats for ascitic hepatoma
AH-66 and AH-l09A. Each group consisted of 10 animals unless the number
of animals is indicated.
Tumors: Ascitic Ehrlich carcinoma and sarcoma-l80, and ascitic hepatoma
AH-66 and AH-109A were harvested six to seven days after intraperitoneal (i. p.)
transplantation. As for intravenous (i. v.) inoculation, tumor cells were washed
three times with ice cold phosphate buffered saline (PBS) solution and the cell
number was adjusted to a repuired concentration. One tenth ml of the cell
suspension was inoculated via tail vein.
Administration of agents: Agents were dissolved in isotonic saline solution
(ISS) at required concentrations and were administered i. p. for the period and
at the dosage as indicated in the results.
To control group in each experiments, ISS was given for equivalent
periods.
In vitro-in vivo test: Tumor cells were washed and suspended in PBS solu-
tion (pH 7.2) at a concentration of 5x 107 /ml. Adding the agents in concentra-
tions shown in the results, the cells were incubated at 37 u C for 60 minutes. The
cells were subsequently washed once, and inoculated to mice i. p. at a count of
5x 10 13 • Survival thereafter was evaluated as an indicator of cytocydal effect of
agents on tumor cells in vitro.
Nitrogen mustard N-Oxide (Nitromin) incorporation into tumor cells: One milli-
liter of packed cells of sarcoma-l80 was suspended in two ml of PBS solution,
to which Nitromin and OK-432 were added at dosage of 100 pg and 2KE respec-
tively, followed by incubation at 37°C. The Nitromin concentration in the
cells was determined as a function of time by the NBP method (4) after washing
three times with ice cold saline solution.
RESULTS
The effect of combined use of OK-432 with MMC on Ehrlich carcinoma
and sarcoma-IBO was first studied in in vitro-in vizo test (Figs. 1, 2).
For both tumors, the cells were treated and inoculated as described above,
and survival thereafter revealed that OK-432 was not cytotoxic on Ehrlich
carcinoma as well as sarcoma-lBO in vitro. MMC showed a fairly strong
effect on Ehrlich carcinoma and a moderate effect on sarcoma-IBO. When
both were used together, even with a concentration of MMC which had been
reduced to one half, a still stronger effect-one that may even be regarded
synergistic - was observed.
In the same way, we examined the effect of combined use of OK-432
with Nitromin on sarcoma-lBO, and completely the same effect as with MMC
was observed (Fig. 3).
Next, we studied in the same way the minimal effective concentration
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+ OK-432 2KE/ml 1"-__........__.......__.......__........__-.
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days after inoculation
Fig. 1. Effect of combined use of OK-432 with
MMC on sarcoma-ISO in in vitro-in vivo test
Tumor cells were incubated together with agents
at a concentration as indicated above. 5 x 106 cells
were inoculated i. p., followed by survival. The
verticaUine indicates percent surviving.
Control o
OK-432 2KE/mi 0
1
.....
MMC l0.ug/ml
10
MMC 5.ug/ml ]
+OK-432 IKE/m' 11..__........__"'-,__....'1-._........' _
20 30 40
days after inoculatin
Fig. 2. Effect of combined use of OK-432 with
MMC on Ehrlich carcinoma in in vitro-in vivo test.
Experiments and symbols are the same as in Fig, 1.
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Control Q
OK-432 IKE/rnl 0
Nitrornin 25IJg/rni ~ ~
504030i20i10
Nitrornin 25!lg/rnl ~
OK-432 IKE/rnl
L----r----r----r:----:":'-"";;
days after inoculation
Fig. 3. Effect of combined use of OK-432 with
Nitromin on sarcoma-lBO in vitro-in vivo test.
Experiment and symbols are the same as in Fig. 1.
Control 0
OK-432 2KE/ml 0
MMC 5,ui/ml 1 ~.
MMC 5Jli/ml] \
OK-432 0, I KE/ml l....._--'__..._...J
l,'---_MMC 5t,i/ml ]OK-432 0.5KE/ml 1
---'---'--"""---"----"'--
MMC 5f/g/ml
OK-432 2KE/ml
~'---------
I 0 20 30 40 50 60
days after inoculation
Fig. 4. Concentration of OK-432 and effect on sarcoma-lBO in combination
with MMC in in vitro- in vivo test.
The tumor cells were incubated together with OK-432 in various concentra-
tions and MMC in a concentration of 5,ug/ml and 5 x 106 cells of which were in-
oculated i. p., followed by survival. The vertical line indicates percent surviving.
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of OK-432 on sarcoma-180 when used in combination with MMC in vitro.
As shown in Fig. 4, OK-432 was thereby found to exhibit a dose-response
relationship: and it was also found that, to achieve effective combined use in
vitro, OK-432 had to be added at a relatively high concentration, O. 5KE/ml.
As mentioned above, the combined use of OK-432 with some anticancer
agents definitely proved effective in vitro. As one of the attempts to clarify
the mechanism of action in combination use, the effect of OK-432 on the
incorporation of Nitromin into tumor cells in vitro was measured. No differ-
ence at all was found between the group to which OK-432 had been added
and that to which no OK-432 had been added (Fig. 5).
0.0
0.50
0.25
10 30 60min.
incubation time
Fig. 5. Nitromin incorporation into sarcoma-ISO
cells in vitro, and the effect of added OK-432.
o Nitromin alone • OK-432 added
Subsequently, the effect of combined use of OK-432 with some anticancer
agents was examined by Lp. inoculation-Lp. administration (Lp.-Lp.) method.
From day 3 after i. p. inoculation of 5 X 106 cells of sarcoma-lBO, i. p.
administration of OK-432 and MMC were made for five days. The survival
thereafter in the group given combi~ed administration of the two agents was
considerably longer than in the groups given either of the individual agents
alone (Fig. 6). The in vivo studies, however, revealed almost the same degree
of increased life-span with OK-432 and MMC, differing from the results
obtained with the in vitro studies.
With AH-66, to which OK-432 alone was effective to some degree,
Bleomycin was found to be definitely effective when used in combination
5
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Fig. 6. Effect of combined use of OK-432
with MMC on sarcoma-lBO.
From day 3 after i. p. inoculation, IKEj
mouse of OK-432 and O. 25mgjkg of MMC were
given i. p. for 5 days.
The vertical line indicates percent surviving.
charactor of this agent does not
exclude possible host-mediated ac-
tion.. Studies were therefore also
made in this respect.
Mice pretreated i. p. with OK-
432 were inoculated with Ehrlich
carcinoma i. v. via tail vein five
days after completion of pretreat-
ment, and survival thereafter was
studied (Fig. 10). As presented in
the figure, the survival rate of the
group pretreated with the agents
was about twice as high as in the
control group at 40 days after in-
oculation.
We now report the clinical
results.
The initial dose of OK-432
was O.IKE, which was then gradu-
ally raised to a maintenance dose
I
10
with OK-432 (Fig. 7). One the
other hand, AH-I09A was almost
insensitive to OK-432, and the com-
bined use of OK-432 with 864-T or
MMC was found not to be more
effective than with 864-T or MMC
alone (Fig. 8).
Next, we used the i. v. inocu-
lation-i. p. administration .(i. v.-i. p.)
method to establish whether or not
the combined use was effective
upon Ehrlich carcinoma inoculated
at different sites (Fig. 9). The
agents were administered i. p. from
day 3 after i. v. inoculation as
shown in the figure, and this ad-
ministration of agents turned out to
be completely ineffective.
The results thus far described
mainly indicate the direct action of
OK-432 against tumor cells. The
I ,
20 30 40
days after inoculation
Fig. 7. Effect of combined use of OK-432
with Bleomycin on AH-66.
4mgjkg of Bleomycin and 2KEjrat of OK-
432 were administered i.p. from day 3 after i.p.
inoculation of 5 X 106 of tumor cells for 10 days.
Bleomyc;n 1_~~----,-~_-_
Cont,o' ~
OK-432 Q"--_---. _
Bleomycin ~
+ OK'"432
I--._~~-~~---'----
5040
days after inoculation
302010
Dcontrol
MMC
OK-432
MMC
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Control
OK-432
417
CPA.
OK-432
CPA.
OK-432
Control 1----'-----'~
1---,---,~---"
Mnomyoo C 1 ....L-_~
1---!--~~
1"---~~___'
1'------:-'::1O:----~--:::!'='20
days after inoculation
Fig. 9. Combined use of OK-432 with
MMC or Cyclophosphamide (CPA) on Ehrlich
carcinoma in i. v. -i. p. method.
5 X 106 of tumor cells washed 3 times in ice
cold PBS solution were inoculated i. v. via tail
vein. From day 3 after inoculation, IKE/mouse
of OK-432 and O. 33 mg/kg of MMC or lOmg/kg
of CPA were given i. p. for 10 days.
MitomYCin C
OK-432
864-T
1~~---,--,
l"---'-------.I~
l---....-,~~-'---
~~~-4321....__.........~"'---_'=.-=--=--=.-=--=--=--=--
1,",---",---~~,===
:,
20 30
days after inoculation
Fig. 8. Combined use of OK-432 with
MMC or 864-T on AH-109A.
2KE/rat of OK-432 and O.2mg/kg of
MMC or 10 mg/kg of 864-T were given
i. p. from day 3 after i. p. inoculation of
5 X 106 cells of AH-109A for 7 days.
864-T ]
+OK-4321
'---~:----::b::---~--
Survival rates
on the 40th day
control 31.3%
1
.....L..__--,
~L. _
OK -432 :...-__--.- --.- .....- _
56.3%
10 20 30
days after inoculation
Fig. 10. Effect of pretreatment with OK-432 on survival after
i. v. inoculation of Ehrlich carcinoma.
Pretreatment with IKE/mouse of OK-432 was made for 7 days.
Five days later, 2 X 106 of Ehrlich carcinoma were inoculated via tail
vein, followed by survival. Each group consisted of 15 to 16 mice.
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of 0.5 to 2. OKE, through i. v. drip infusion twice a week as a rule. :MMC
or Cyclophosphamide (CPA) was given at a dosage of 6mg or 400 mg twice
a week as a one-shot i. v. infusion.
This treatment was given to 14 cases so far. Eight of these cases had
advanced lung cancer, and most of other cases were at a late stage accom-
panied with ascites or plerual effusion. The treatment proved effective in 5
of 8 cases with lung cancer, but did not bring about any definite evidence of
improvement in the cases with liver cancer and other cases (Table 1).
TABLE 1 CLINICAL RERPONSE IN PATIENTS TREATED WITH COMBINED USE OF
OK-432 AND MITOMYCIN C OR CYCLOPHOSPHAMIDE (CPA).
Case total dosis
No. Age Sex Disease Response Side EffectsOK-432 MMC CPA
1 56 M Ca. of the lung 9O.2KE 64mg 4800mg + fever
2 68 M Ca. of the lung 5.0 48 ++ fever
3 59 M Ca. of the lung 83.0 88 ++ fever
4 58 M Ca. of the lung 7.4 48 fever, leucopenia
5 68 M Ca. of the lung 57.6 42 3600 fever
6 62 M Ca. of the lung 17.3 42 + fever
7 72 M Ca. of the lung 12.5 60 fever
8 66 M Ca. of the lung 5.4 54 + fever
9 48 M Ca. of the liver 170.0 3200 fever, leucopenia
10 59 F Ca. of the liver 8.5 64 fever
11 68 M Ca. of the liver 15.0 88 fever
12 64 F Ca. of the stomach 108.5 40
13 48 F Ca. of the stomach 49.0 54
14 73 F Ca. of the breast 17.5 48 fever, leucopenia
++: more than 50% reduction of tumor in diameter
+ : more than 25% reduction of tumor in diameter
Figs. 11 and 12 show the changes of peripheral blood counts in the cases
during chemotherapy. White blood cell counts tended, if anything, to show
a temporary increase following initiation of the treatment. A decline less
than 3,000/cmm was seen in only one case. Within one to three hr after i. v.
infusion of OK-432, fever with chills were observed in 11 of the 14 cases.
DISCUSSION
We have thus far briefly outlined the results of experimental studies and
the clinical application of combined administration of OK-432 with anti-
cancer agents. According to OKAMOTO (l) , KOSHIMURA et ala (5) , the anti-
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Platelet
(x 104 )
419
2 4 6 8 10 2 4 6 8 \0
weeks after the initiation of therapy
Fig. 11. Changes in white blood cell counts and platelet counts in cases
given OK-432 together with MMC or CPA.
16
Hb(gjdl)
2 4 6 8 10 4 6 8
weeks after the initiation of therapy
Fig. 12. Changes in red blood cell counts and hemoglobin content in cases
given OK-432 together with MMC or CPA.
cancer mechanism of action of the hemolytic streptococcus is understood to
be as follows: The hemolytic streptococcus acts upon tumor cells as an
enzyme to produce streptolysin S, with the cell RNA functioning as a sub-
strate, resulting in the loss of RNA and the devastation of RNA metabolism.
In our in vitro-in vivo studies, OK-432 alone was not found effective.
Yet, when OK-432 was used together with MMC or Nitromin, the in vitro- in
vivt) tests established a considerably higher effectiveness than by the use of
those drugs alone, a difference is so remarkable that it might even be regarded
as synergistic. OK-432 is thereby inferred to have an action which, if not
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cytocidal, still produces fairly substantial damage within the cells, and,
together with the action of the anti-cancer antibiotic or alkylating agent, may
be presumed responsible for lethal damage to the tumor cells.
OK-432 consists of the bacterial cell itself, deprived of its ability to
multiply. If OK-432 has a direct action on tumor cells, the first presumption
must be that bacterial cells come into contact with the tumor cell membrane,
with the subsequent occurrence of some interference phenomenon or others.
From this viewpoint, it was conjectured that this drug might affect the in-
corporation of anticancer agents into the cells. The concentration of Nitro-
min incorporated into the cells following the addition of the present drug
was therefore determined. The findings obtained tended to exclude this
possible effect on the incorporation of anti-cancer agents into the cells.
The effect of OK-432 in vivo has been reported to be highest in Ehrlich
carcinoma, followed by some rat ascitic hepatoma and Yoshida sarcoma
resistant to Nitromin. These results were mostly obtained in i.p.-i.p: studies,
in which the effect appeared most readily (6, 7).
In the present studies, the dosage of OK-432 was IKE/mouse (about 30
KE/kg and 2 KE/rat (about 13 KE/kg). The above dosage was approximately
equivalent to the minimal effective dosis on sarcoma-lBO, Ehrlich carcinoma,
and AH-66 by the i.p.-i.p. method. When used simultaneously with effective
dose of MMC and Bleomycin, OK-432 produced a remarkable effect closely
paralleling the results of the in ritro studies. In AH-I09A that failed to
respond to OK-432 alone, the use of this drug in combination with an effec-
tive dose of MMC or B64-T did not show any benefit. The marked effec-
tiveness of combined administration, already indicated, should be regarded
as obtainable only when used on tumors which are sensitive in some degree
to OK-432 and the combined agents. In Ehrlich carcinoma that proved amen-
able by i. p.-i. p. method, no effect of OK-432 alone or in combination with
another drug was observed even at the same dosage in the case of i. v.-i. p.
method, which gave reduced accessibility of the drugs to the tumor focus.
The above-described results support the interpretation that the effect of
OK-432 arises from its direct action on the tumor. Since the drug is of
bacterial origin, the possibility of host mediation in addition to the direct
action should also be fully considered. SAKURAI (B) showed the results with
AH-13 suggesting the presence of some host-mediated action. In our present
studies, also, OK-432 when tested alone showed different results for in vitro
and in vivo studies r Survival rate after tumor inoculation was evidently higher
in the group given pretreatment with the present drug. These findings by no
means exclude the possibility of host mediation.
The number of clinical cases treated with the present drugs is still small.
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In addition, many of the cases were at an advanced stage of the disease.
Thus, the sujects in the present studies were hardly ideal. An attention
should, however, be drawn to the fact that in the cases of lung cancer where
the evaluation of drug effects is easier, the tumor was found to diminish in
five out of 8 cases, although MMC was, of course, used at more than the
minimal effective dose. Further studies appear to be worthwhile.
The OK-432 dose per kg, body weight, was varied with the clinical
cases, but was considerably less than that used on animals. As pointed out
by KUROKAWA et al. (3), there was no relationship observed between the
clinical response and the total dosage. This is another apparent reason for
assuming the presence of host-mediated action.
The combined administration of OK-432 and MMC at least does not
aggravate hematological side effects, but gives, on the contrary, the impres-
sion of lessening them in comparison with cases MMC alone. This, however,
is a matter that remains to be clarified with many more clinical cases.
As stated above, at the present stage of our knowledge about OK-432,
we have to postulate a direct action on the tumor and an indirect acton via the
host. If both these factors should really prove to be involved together in this
drug, its combined administration with anticancer agents may constitute a
special type of combined chemotherapy.
Acknowledgement: The authors express their thanks to Prof. Kiyoshi HIRAKI for direction
over the present studies and for critical perusal of this paper before publication.
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